Developer docs
API playgroundTry for free, no card

Search company profiles

Transcode Therapeutics

Full company profile

uuid00000ny

Namestring
Transcode Therapeutics
Legal namestring
TransCode Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2021
Descriptiontext

TransCode Therapeutics, Inc. is a clinical-stage immuno-oncology and RNA therapeutics company developing treatments for metastatic and advanced cancers. The company is built around its proprietary TTX (Targeted Delivery) Platform, an iron oxide nanoparticle delivery system functionalized with dextran and amino groups that is designed to transport therapeutic oligonucleotides (antisense oligos, siRNA, mRNA, RIG-I agonists) to tumors and metastatic sites, and which is described as benefiting from a 30+ year clinical safety record from related iron oxide nanoparticle use in humans.

The lead asset, TTX-MC138, is a first-in-class antagomiR targeting microRNA-10b, a master regulator of metastatic tumor cell viability. The company completed Phase 1a dose escalation and in May 2026 initiated a Phase 2a trial in ctDNA-positive colorectal cancer. The broader pipeline includes TTX-siPDL1 (FDA Orphan Drug Designation in pancreatic cancer), TTX-RIGA, TTX-CRISPR, 64Cu-TTX-MC138 (a radiotheranostic for PET imaging), and TTX-mRNA (cancer vaccine). The portfolio was expanded in October 2025 with the Polynoma acquisition, which added the melanoma vaccine candidate Seviprotimut-L, and in March 2026 via an exclusive license from Unleash Immuno Oncolytics covering UIO-524/525/526, an oncolytic immunotherapy directed at muscle-invasive bladder cancer and other solid tumors.

The company is pre-revenue with no approved products. Its business model centers on advancing investigational assets through clinical milestones while pursuing inbound licensing arrangements for the TTX platform and pipeline candidates across immunotherapy, gene editing, radiotherapy, cancer vaccines, diagnostics, and targeted therapies. Capital is sourced from equity financings (approximately $100 million raised since the 2021 NASDAQ IPO under ticker RNAZ) and NIH non-dilutive grants. Headquartered in Boston, Massachusetts with 11–50 employees, the company reported a trailing twelve-month net loss of $27.13 million as of December 2025, with the stock declining more than 91% year-to-date and management identifying ability to continue as a going concern as a forward-looking risk.

Short descriptiontext

TransCode Therapeutics is a clinical-stage RNA oncology and immuno-oncology company developing therapeutics for metastatic and advanced cancers via its proprietary TTX iron oxide nanoparticle delivery platform, with lead asset TTX-MC138 in Phase 2a trials for colorectal cancer and a broadened pipeline acquired via Polynoma and licensed from Unleash Immuno Oncolytics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewton, United States
HQ citystring
Newton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA oncology therapeutics, metastatic cancer treatment, nanoparticle drug delivery, microRNA cancer therapy, immuno-oncology pipeline
Industry7 codes
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
RNA Oncology Therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1No Product Revenue (Pre-Commercial Clinical Stage)
TypeLicensing Royalties
Description

TransCode is a clinical-stage company with no commercial products and no product revenue. The company has been investing approximately $100 million since its 2021 IPO through equity financing and government-funded non-dilutive grants. Net loss was $27.13 million over the trailing twelve months. Future revenue potential would derive from licensing deals, partnerships, and eventually product commercialization (none of which are currently active revenue streams).

in.investing.com
2Non-Dilutive Government Grant Funding
TypeLicensing Royalties
Description

NIH grants supporting clinical development of TTX-MC138 and pipeline candidates, including a $2 million Direct to Phase II SBIR grant (2024) and prior-year grants totaling nearly $871,000 (third-year grant 2023). These provide non-dilutive capital to fund clinical trials.

globenewswire.com
Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1TTX-MC138
Description

Lead therapeutic candidate designed to inhibit microRNA-10b for treating metastatic cancers; first-in-class antagomiR program.

transcodetherapeutics.com
+8 more records
Core offering1 text field

TransCode Therapeutics is a clinical-stage RNA oncology company that develops and commercializes drugs for the treatment of metastatic cancer. Its core offering is the proprietary TTX iron oxide nanoparticle delivery platform used to deliver therapeutic oligonucleotides (antisense, siRNA, mRNA, RIG-I agonists) to tumors and metastases. The lead clinical candidate TTX-MC138 inhibits microRNA-10b and is currently being evaluated in Phase 1a/2a clinical trials for metastatic cancers, with a broader pipeline spanning immunotherapy, gene-editing, radiopharmaceutical, and cancer vaccine candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 64% (9/14 evaluable patients) achieved stable disease lasting six months in Phase 1a trial
+6 more records
Product overview1 text field

TransCode Therapeutics operates as a clinical-stage oncology company organized around its proprietary TTX Delivery Platform — iron-oxide magnetic nanoparticles engineered to ferry therapeutic nucleic acids into tumors and metastatic cells. The lead asset, TTX-MC138 (a microRNA-10b inhibitor), has completed Phase 1a and entered Phase 2a, while the broader pipeline extends across TTX-siPDL1 (an FDA Orphan-Designated siRNA targeting PD-L1 for pancreatic cancer), TTX-RIGA (RIG-I immunotherapy), TTX-CRISPR (gene-editing), 64Cu-TTX-MC138 (radiopharmaceutical imaging/diagnostic), TTX-mRNA (cancer vaccine), and a miRNA detection diagnostic platform. The portfolio was further broadened through the October 2025 acquisition of Polynoma, which added the melanoma vaccine Seviprotimut-L, and the March 2026 license of UIO-524, UIO-525, and UIO-526 from Unleash Immuno Oncolytics for muscle-invasive bladder cancer.

Product and service12 records
1TTX-MC138
CategoryLead therapeutic candidate (microRNA-10b inhibitor)
2TTX Delivery Platform
CategoryCore platform technology
3TTX-siPDL1
CategoryImmunotherapy candidate (RNAi)
4TTX-RIGA
CategoryImmunotherapy candidate (innate immune activator)
5TTX-CRISPR
CategoryGene-editing candidate
664Cu-TTX-MC138
CategoryRadiopharmaceutical / diagnostic candidate
7TTX-mRNA
CategoryCancer vaccine candidate
8Seviprotimut-L
CategoryAcquired therapeutic candidate (melanoma vaccine)
9UIO-524
CategoryOncolytic immunotherapy candidate (licensed)
10UIO-525
CategoryOncolytic immunotherapy candidate (licensed)
11UIO-526
CategoryOncolytic immunotherapy candidate (licensed)
12miRNA Detection Diagnostics
CategoryDiagnostics platform
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagship / CoreTypeStrategic or Co-development PartnerAnnounced on2026-05-27
Description

Collaboration for Phase 2a clinical trial of TTX-MC138 in ctDNA-positive colorectal cancer under the PRE-I-SPY platform. Trial expected to enroll up to 45 patients with principal investigators from University of Minnesota and Mayo Clinic Comprehensive Cancer Center, and trial chair from MD Anderson Cancer Center. QLHC sponsors and manages the I-SPY Trial programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-27
Description

Sponsored research agreement announced April 2026 to accelerate development of pipeline candidates, including evaluation of lead therapeutic TTX-MC138 in combination with Seviprotimut-L and standard-of-care therapies for potential synergies. Dr. Anna Moore (TransCode co-founder) serves as Associate Dean for Research Development at Michigan State University.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-27
Description

Phase 2a trial in colorectal cancer led by Dr. Emil Lou (University of Minnesota) and Dr. Zhaohui Jin (Mayo Clinic Comprehensive Cancer Center) as principal investigators, and Dr. Paula Pohlmann (MD Anderson Cancer Center) as trial chair. Clinical sites include National Comprehensive Cancer Network (NCCN) members.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-03
Description

TransCode entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics to develop three preclinical drug candidates: UIO-524 (lead, next-generation oncolytic immunotherapy for muscle-invasive bladder cancer), UIO-525, and UIO-526, targeting solid tumors. Consideration: 1,136,364 shares of non-voting convertible preferred stock representing 6.8% of TransCode's fully diluted common stock. Tungsten Advisors acted as exclusive financial advisor.

Strategic tierFlagship / CoreTypeStrategic or Co-development PartnerAnnounced on2025-10-08
Description

TransCode acquired Polynoma, LLC (parent of ABCJ, LLC) from DEFJ, LLC in October 2025 for Series A Preferred Stock plus up to $95 million in milestone payments. The acquisition includes Polynoma's late-stage melanoma vaccine candidate seviprotimut-L, expanding TransCode's immuno-oncology pipeline.

Strategic tierFlagship / CoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-01-01
Description

TransCode executed an exclusive option agreement with Massachusetts General Hospital for 64Cu-TTX-MC138, under which TransCode has the right to negotiate an exclusive license for this asset. The company's scientific co-founders (Anna Moore, Zdravka Medarova) spent 26 years at MGH and Harvard Medical School.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage leader in RNAi therapeutics with a GalNAc-conjugate delivery platform for liver-targeted diseases. Alnylam is the most relevant comparable for TransCode given its focus on RNA-targeted therapeutics and platform-based drug development, though Alnylam is much further advanced commercially.

TypeDirect peer
Description

mRNA therapeutics platform company with oncology vaccine and intratumoral immuno-oncology programs. Both companies develop RNA-based oncology therapeutics and pursue modular platform strategies, though Moderna's lipid nanoparticle delivery differs from TransCode's TTX iron-oxide nanoparticle system.

TypeDirect peer
Description

Clinical-stage RNAi therapeutics company developing multiple siRNA-based candidates using its proprietary TRiM delivery platform targeting oncology, cardiometabolic, and other indications. Closely comparable to TransCode's pipeline and platform-based approach.

TypeDirect peer
Description

Clinical-stage mRNA medicines company with a lipid-mediated delivery platform and oncology programs including personalized cancer vaccines. Comparable in stage, RNA modality, and pipeline diversity, though Arcturus has a more developed LNP-based delivery approach.

TypeBroad incumbent
Description

Established antisense oligonucleotide (ASO) therapeutics company with a broad pipeline including oncology and rare disease programs. Both companies develop ASO-based RNA therapeutics, though Ionis has multiple approved products and a much more advanced commercial footprint.

TypeBroad incumbent
Description

Major mRNA therapeutics company with oncology vaccine programs (including individualized neoantigen vaccines) and a delivery platform. Both companies pursue RNA-based cancer therapeutics, though BioNTech has substantially greater resources and a more advanced pipeline.

TypeDirect peer
Description

Clinical-stage RNAi therapeutics developer with a GalNAc-conjugate platform (acquired by Novo Nordisk). Dicerna is comparable to TransCode as a clinical-stage RNAi platform company, though Dicerna focused on liver-targeted indications before its acquisition.

TypeDirect peer
Description

Clinical-stage RNAi therapeutics company developing siRNA-based drugs with its mRNAi GOLD platform. Closely comparable in modality (siRNA), platform approach, and clinical stage, though Silence has progressed further in cardiovascular and rare disease indications.

TypeEmerging player
Description

Clinical-stage RNA therapeutics company developing saRNA (small activating RNA) drugs, with an oncology focus. Comparable in modality (RNA therapeutics), platform-based approach, and clinical stage, though MiNA's saRNA mechanism differs from TransCode's miRNA inhibition approach.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing RNAi-based therapeutics using its self-delivering INTASYL platform. Comparable as a small-cap clinical-stage RNAi oncology company developing novel delivery approaches for RNA-based cancer therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Transcode Therapeutics

RNA Oncology Therapeuticstranscodetherapeutics.com

TransCode Therapeutics is a clinical-stage RNA oncology and immuno-oncology company developing therapeutics for metastatic and advanced cancers via its proprietary TTX iron oxide nanoparticle delivery platform, with lead asset TTX-MC138 in Phase 2a trials for colorectal cancer and a broadened pipeline acquired via Polynoma and licensed from Unleash Immuno Oncolytics.

What Transcode Therapeutics does

TransCode Therapeutics, Inc. is a clinical-stage immuno-oncology and RNA therapeutics company developing treatments for metastatic and advanced cancers. The company is built around its proprietary TTX (Targeted Delivery) Platform, an iron oxide nanoparticle delivery system functionalized with dextran and amino groups that is designed to transport therapeutic oligonucleotides (antisense oligos, siRNA, mRNA, RIG-I agonists) to tumors and metastatic sites, and which is described as benefiting from a 30+ year clinical safety record from related iron oxide nanoparticle use in humans.

The lead asset, TTX-MC138, is a first-in-class antagomiR targeting microRNA-10b, a master regulator of metastatic tumor cell viability. The company completed Phase 1a dose escalation and in May 2026 initiated a Phase 2a trial in ctDNA-positive colorectal cancer. The broader pipeline includes TTX-siPDL1 (FDA Orphan Drug Designation in pancreatic cancer), TTX-RIGA, TTX-CRISPR, 64Cu-TTX-MC138 (a radiotheranostic for PET imaging), and TTX-mRNA (cancer vaccine). The portfolio was expanded in October 2025 with the Polynoma acquisition, which added the melanoma vaccine candidate Seviprotimut-L, and in March 2026 via an exclusive license from Unleash Immuno Oncolytics covering UIO-524/525/526, an oncolytic immunotherapy directed at muscle-invasive bladder cancer and other solid tumors.

The company is pre-revenue with no approved products. Its business model centers on advancing investigational assets through clinical milestones while pursuing inbound licensing arrangements for the TTX platform and pipeline candidates across immunotherapy, gene editing, radiotherapy, cancer vaccines, diagnostics, and targeted therapies. Capital is sourced from equity financings (approximately $100 million raised since the 2021 NASDAQ IPO under ticker RNAZ) and NIH non-dilutive grants. Headquartered in Boston, Massachusetts with 11–50 employees, the company reported a trailing twelve-month net loss of $27.13 million as of December 2025, with the stock declining more than 91% year-to-date and management identifying ability to continue as a going concern as a forward-looking risk.

Transcode Therapeutics firmographics

Firmographics
Name
Transcode Therapeutics
Legal name
TransCode Therapeutics, Inc.
Website
https://transcodetherapeutics.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
TransCode Therapeutics is a clinical-stage RNA oncology and immuno-oncology company developing therapeutics for metastatic and advanced cancers via its proprietary TTX iron oxide nanoparticle delivery platform, with lead asset TTX-MC138 in Phase 2a trials for colorectal cancer and a broadened pipeline acquired via Polynoma and licensed from Unleash Immuno Oncolytics.
Ownership category
akta.pro rank

Transcode Therapeutics industry classification

Industry
Product category
RNA Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • RNA oncology therapeutics
  • Metastatic cancer treatment
  • Nanoparticle drug delivery
  • MicroRNA cancer therapy
  • Immuno-oncology pipeline

Where Transcode Therapeutics is headquartered

Location

Headquarters

HQ city
Newton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Transcode Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. No Product Revenue (Pre-Commercial Clinical Stage): TransCode is a clinical-stage company with no commercial products and no product revenue. The company has been investing approximately $100 million since its 2021 IPO through equity financing and government-funded non-dilutive grants. Net loss was $27.13 million over the trailing twelve months. Future revenue potential would derive from licensing deals, partnerships, and eventually product commercialization (none of which are currently active revenue streams).
  2. Non-Dilutive Government Grant Funding: NIH grants supporting clinical development of TTX-MC138 and pipeline candidates, including a $2 million Direct to Phase II SBIR grant (2024) and prior-year grants totaling nearly $871,000 (third-year grant 2023). These provide non-dilutive capital to fund clinical trials.

Go-to-market motion2 records

Distribution channels4 records

Transcode Therapeutics product offering

Product offering

Core offering

TransCode Therapeutics is a clinical-stage RNA oncology company that develops and commercializes drugs for the treatment of metastatic cancer. Its core offering is the proprietary TTX iron oxide nanoparticle delivery platform used to deliver therapeutic oligonucleotides (antisense, siRNA, mRNA, RIG-I agonists) to tumors and metastases. The lead clinical candidate TTX-MC138 inhibits microRNA-10b and is currently being evaluated in Phase 1a/2a clinical trials for metastatic cancers, with a broader pipeline spanning immunotherapy, gene-editing, radiopharmaceutical, and cancer vaccine candidates.

Product overview

TransCode Therapeutics operates as a clinical-stage oncology company organized around its proprietary TTX Delivery Platform — iron-oxide magnetic nanoparticles engineered to ferry therapeutic nucleic acids into tumors and metastatic cells. The lead asset, TTX-MC138 (a microRNA-10b inhibitor), has completed Phase 1a and entered Phase 2a, while the broader pipeline extends across TTX-siPDL1 (an FDA Orphan-Designated siRNA targeting PD-L1 for pancreatic cancer), TTX-RIGA (RIG-I immunotherapy), TTX-CRISPR (gene-editing), 64Cu-TTX-MC138 (radiopharmaceutical imaging/diagnostic), TTX-mRNA (cancer vaccine), and a miRNA detection diagnostic platform. The portfolio was further broadened through the October 2025 acquisition of Polynoma, which added the melanoma vaccine Seviprotimut-L, and the March 2026 license of UIO-524, UIO-525, and UIO-526 from Unleash Immuno Oncolytics for muscle-invasive bladder cancer.

Differentiator

Problem solved

Functional benefit

Brands

  • TTX-MC138: Lead therapeutic candidate designed to inhibit microRNA-10b for treating metastatic cancers; first-in-class antagomiR program.
  • TTX
  • TTX-siPDL1
  • TTX-RIGA
  • 64Cu-TTX-MC138
  • Seviprotimut-L
  • UIO-524
  • UIO-525
  • UIO-526

Products and services

  • TTX-MC138
  • TTX Delivery Platform
  • TTX-siPDL1
  • TTX-RIGA
  • TTX-CRISPR
  • 64Cu-TTX-MC138
  • TTX-mRNA
  • Seviprotimut-L
  • UIO-524
  • UIO-525
  • UIO-526
  • miRNA Detection Diagnostics

Quantifiable outcome

  • 64% (9/14 evaluable patients) achieved stable disease lasting six months in Phase 1a trial
  • +6 more outcomes

Companies that use Transcode Therapeutics

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles2 records

Transcode Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Transcode Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship / core and core.

  • Quantum Leap Healthcare Collaborative (QLHC)flagship / coreStrategic or Co-development Partner · 27 May 2026Collaboration for Phase 2a clinical trial of TTX-MC138 in ctDNA-positive colorectal cancer under the PRE-I-SPY platform. Trial expected to enroll up to 45 patients with principal investigators from University of Minnesota and Mayo Clinic Comprehensive Cancer Center, and trial chair from MD Anderson Cancer Center. QLHC sponsors and manages the I-SPY Trial programs.
  • Michigan State UniversitycoreStrategic or Co-development Partner · 27 April 2026Sponsored research agreement announced April 2026 to accelerate development of pipeline candidates, including evaluation of lead therapeutic TTX-MC138 in combination with Seviprotimut-L and standard-of-care therapies for potential synergies. Dr. Anna Moore (TransCode co-founder) serves as Associate Dean for Research Development at Michigan State University.
  • University of Minnesota, Mayo Clinic Comprehensive Cancer Center, MD Anderson Cancer CentercoreImplementation/ SI/ Consulting Partner · 27 April 2026Phase 2a trial in colorectal cancer led by Dr. Emil Lou (University of Minnesota) and Dr. Zhaohui Jin (Mayo Clinic Comprehensive Cancer Center) as principal investigators, and Dr. Paula Pohlmann (MD Anderson Cancer Center) as trial chair. Clinical sites include National Comprehensive Cancer Network (NCCN) members.
  • Unleash Immuno Oncolytics, Inc.coreOEM/ Whitelabel/ Licensing Partner · 3 March 2026TransCode entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics to develop three preclinical drug candidates: UIO-524 (lead, next-generation oncolytic immunotherapy for muscle-invasive bladder cancer), UIO-525, and UIO-526, targeting solid tumors. Consideration: 1,136,364 shares of non-voting convertible preferred stock representing 6.8% of TransCode's fully diluted common stock. Tungsten Advisors acted as exclusive financial advisor.
  • Polynoma, LLC (parent of ABCJ, LLC)flagship / coreStrategic or Co-development Partner · 8 October 2025TransCode acquired Polynoma, LLC (parent of ABCJ, LLC) from DEFJ, LLC in October 2025 for Series A Preferred Stock plus up to $95 million in milestone payments. The acquisition includes Polynoma's late-stage melanoma vaccine candidate seviprotimut-L, expanding TransCode's immuno-oncology pipeline.
  • Massachusetts General Hospital (MGH)flagship / coreOEM/ Whitelabel/ Licensing Partner · 1 January 2021TransCode executed an exclusive option agreement with Massachusetts General Hospital for 64Cu-TTX-MC138, under which TransCode has the right to negotiate an exclusive license for this asset. The company's scientific co-founders (Anna Moore, Zdravka Medarova) spent 26 years at MGH and Harvard Medical School.

Scale indicators11 records

Recent moves7 records

Expansion highlights7 records

Transcode Therapeutics competitors and assessment

Company assessment

Direct peers

  • Alnylam Pharmaceuticals: Commercial-stage leader in RNAi therapeutics with a GalNAc-conjugate delivery platform for liver-targeted diseases. Alnylam is the most relevant comparable for TransCode given its focus on RNA-targeted therapeutics and platform-based drug development, though Alnylam is much further advanced commercially.
  • Moderna: mRNA therapeutics platform company with oncology vaccine and intratumoral immuno-oncology programs. Both companies develop RNA-based oncology therapeutics and pursue modular platform strategies, though Moderna's lipid nanoparticle delivery differs from TransCode's TTX iron-oxide nanoparticle system.
  • Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company developing multiple siRNA-based candidates using its proprietary TRiM delivery platform targeting oncology, cardiometabolic, and other indications. Closely comparable to TransCode's pipeline and platform-based approach.
  • Arcturus Therapeutics: Clinical-stage mRNA medicines company with a lipid-mediated delivery platform and oncology programs including personalized cancer vaccines. Comparable in stage, RNA modality, and pipeline diversity, though Arcturus has a more developed LNP-based delivery approach.
  • Dicerna Pharmaceuticals (Novo Nordisk): Clinical-stage RNAi therapeutics developer with a GalNAc-conjugate platform (acquired by Novo Nordisk). Dicerna is comparable to TransCode as a clinical-stage RNAi platform company, though Dicerna focused on liver-targeted indications before its acquisition.
  • Silence Therapeutics: Clinical-stage RNAi therapeutics company developing siRNA-based drugs with its mRNAi GOLD platform. Closely comparable in modality (siRNA), platform approach, and clinical stage, though Silence has progressed further in cardiovascular and rare disease indications.

Broad incumbents

  • Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) therapeutics company with a broad pipeline including oncology and rare disease programs. Both companies develop ASO-based RNA therapeutics, though Ionis has multiple approved products and a much more advanced commercial footprint.
  • BioNTech: Major mRNA therapeutics company with oncology vaccine programs (including individualized neoantigen vaccines) and a delivery platform. Both companies pursue RNA-based cancer therapeutics, though BioNTech has substantially greater resources and a more advanced pipeline.

Emerging players

  • MiNA Therapeutics: Clinical-stage RNA therapeutics company developing saRNA (small activating RNA) drugs, with an oncology focus. Comparable in modality (RNA therapeutics), platform-based approach, and clinical stage, though MiNA's saRNA mechanism differs from TransCode's miRNA inhibition approach.
  • Phio Pharmaceuticals: Clinical-stage immuno-oncology company developing RNAi-based therapeutics using its self-delivering INTASYL platform. Comparable as a small-cap clinical-stage RNAi oncology company developing novel delivery approaches for RNA-based cancer therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Transcode Therapeutics social profiles

Digital presence

Transcode Therapeutics compliance and trust

Trust signal

Compliance1 record

Transcode Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Transcode Therapeutics leadership team

Management profile

Number of profiles

Profiles19 records

Transcode Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Transcode Therapeutics funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Transcode Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transcode Therapeutics

What does Transcode Therapeutics do?

TransCode Therapeutics is a clinical-stage RNA oncology company that develops and commercializes drugs for the treatment of metastatic cancer. Its core offering is the proprietary TTX iron oxide nanoparticle delivery platform used to deliver therapeutic oligonucleotides (antisense, siRNA, mRNA, RIG-I agonists) to tumors and metastases. The lead clinical candidate TTX-MC138 inhibits microRNA-10b and is currently being evaluated in Phase 1a/2a clinical trials for metastatic cancers, with a broader pipeline spanning immunotherapy, gene-editing, radiopharmaceutical, and cancer vaccine candidates.

Is Transcode Therapeutics a public or private company?

Transcode Therapeutics is a public company. It is classified as public and is currently operating.

When was Transcode Therapeutics founded?

Transcode Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Transcode Therapeutics based?

Transcode Therapeutics is headquartered in Newton, United States, in the North America region.

How does Transcode Therapeutics make money?

Two revenue lines are on record. No Product Revenue (Pre-Commercial Clinical Stage) is the primary driver. The others are non-Dilutive Government Grant Funding.

Who are Transcode Therapeutics's main competitors?

Direct peers on record are Alnylam Pharmaceuticals, Moderna, Arrowhead Pharmaceuticals, Arcturus Therapeutics, Dicerna Pharmaceuticals (Novo Nordisk) and Silence Therapeutics. Broad incumbents are Ionis Pharmaceuticals and BioNTech. Emerging players are MiNA Therapeutics and Phio Pharmaceuticals.

Does Transcode Therapeutics have an API?

No public API is recorded for Transcode Therapeutics.

What industry is Transcode Therapeutics in?

Transcode Therapeutics's product category is RNA Oncology Therapeutics. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialBiomednewsbreaks - Transcode Therapeutics, Inc. (NASDAQ: RNAZ) Initiates Strategic Review To Maximize Value Of Oncology PortfolioTranscode Therapeutics initiated a strategic review to maximize value of its oncology portfolio, including TTX-MC138, an RNA-based therapeutic targeting microRNA-10b. The drug advanced to Phase 2a for colorectal cancer patients with circulating tumor DNA-positive disease, following Phase 1a safety data and stable disease reports. The review may not result in a transaction.Investing.comTransCode Therapeutics explores strategic alternativesTransCode Therapeutics' board initiated a formal strategic process to evaluate transactions involving its oncology portfolio, engaging Tungsten Advisors. The company's lead candidate TTX-MC138 is in Phase 2a for colorectal cancer, with 10 of 14 patients achieving stable disease. No transaction is assured.Stock TitanTransCode hires Tungsten for strategic portfolio reviewTransCode Therapeutics initiated a formal strategic process to evaluate potential transactions, including asset sales and partnerships, with Tungsten Advisors as exclusive financial advisor. Its lead candidate TTX-MC138 continues in Phase 2a clinical development for ctDNA-positive colorectal cancer, with a collaboration with Natera announced on October 13, 2026.American Banking and Market NewsTransCode Therapeutics (NASDAQ:RNAZ) Stock Falls 2.1% – Time to Sell?TransCode Therapeutics shares fell 2.1% on Tuesday, trading as low as $1.65. Weiss Ratings reissued a sell rating, and the company reported a $7.17 loss per share for the quarter. The stock's consensus rating is Sell.Investing.comTransCode presents phase 1a trial data for cancer therapyTransCode Therapeutics presented Phase 1a trial data for TTX-MC138 at the ESMO Congress 2026 in Madrid. The study met its primary safety endpoint with no dose-limiting toxicities, and showed dose-dependent plasma exposure and disease stabilization. The therapy is now in a Phase 2a trial under the PRE-I-SPY program.Investing.comTransCode presents phase 1a trial data for cancer therapyTransCode Therapeutics presented Phase 1a trial data for TTX-MC138 at the European Society for Medical Oncology Congress 2026 in Madrid. The study met its primary safety endpoint with no dose-limiting toxicities across four dose levels from 0.8 to 4.8 mg/kg. The company is now evaluating the therapy in a Phase 2a trial under the PRE-I-SPY program.Investing.comTransCode to present phase 1a data at ESMO congressTransCode Therapeutics will present Phase 1a clinical data for its lead candidate TTX-MC138 at the ESMO Congress 2026 in Madrid. The poster highlights results from the Phase 1a evaluation in patients with advanced solid tumors. The company is also evaluating TTX-MC138 in a Phase 2a trial under the PRE-I-SPY program.YahooTransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026TransCode Therapeutics will present Phase 1a clinical trial data for TTX-MC138 at ESMO Congress 2026 in Madrid on October 23, 2026. The poster highlights the first-in-class antagomiR targeting miR-10b in advanced solid tumors. The company also notes ongoing Phase 2a development under the PRE-I-SPY program.Stock TitanTransCode to present TTX-MC138 Phase 1a data at ESMOTransCode Therapeutics will present Phase 1a clinical trial data for TTX-MC138 at ESMO on October 23, 2026. The company will display the data as a poster at the congress.Business & FinancialNetworknewsbreaks Transcode Therapeutics, Inc. (NASDAQ: RNAZ) To Present Updated Phase 1A TTX-MC138 Clinical Data At ESMO Congress 2026TransCode Therapeutics will present updated Phase 1A clinical data for TTX-MC138 at ESMO Congress 2026. The company's lead candidate targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The presentation aims to share results from the ongoing trial.